TMC
SLNO

Trellus Management Company’s Soleno Therapeutics SLNO Stock Holding History

Trellus Management Company’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-841
Closed -$16K – 74
2021
Q1 		$16K Sell
841
-43,333
-98% -$1.4M 0.01% 63
2020
Q4 		$1.28M Buy
44,174
+16,412
+59% +$474K 1.06% 25
2020
Q3 		$1.04M Buy
27,762
+3,333
+14% +$97.4K 1.07% 25
2020
Q2 		$813K Sell
24,429
-5,320
-18% -$231K 0.88% 28
2020
Q1 		$1.06M Hold
29,749
– – 1.9% 13
2019
Q4 		$1.31M Buy
29,749
+9,940
+50% +$254K 2.2% 12
2019
Q3 		$446K Buy
19,809
+1,942
+11% +$62K 0.45% 41
2019
Q2 		$750K Buy
17,867
+1,824
+11% +$63K 1.02% 28
2019
Q1 		$496K Buy
16,043
+4,751
+42% +$126K 0.94% 34
2018
Q4 		$290K Buy
11,292
+1,103
+11% +$32.2K 0.66% 37
2018
Q3 		$330K Buy
10,189
+1,573
+18% +$57.2K 0.48% 46
2018
Q2 		$302K Buy
+8,616
New +$253K 0.45% 47

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Trellus Management Company's SLNO Position: Q2 2021 in Review

Trellus Management Company sold out of Soleno Therapeutics (SLNO) in Q2 2021, closing a stake of 841 shares — an estimated $16K sold.

Trellus Management Company first reported a position in SLNO in Q2 2018 and held it in 12 quarters. The position peaked at $1.31M in Q4 2019. 47 funds tracked by Wall St. Rank hold SLNO as of Q2 2021.

  • Trellus Management Company reported no remaining Soleno Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Trellus Management Company sold 841 Soleno Therapeutics shares in Q2 2021, an estimated $16K.
  • Trellus Management Company first reported a position in Soleno Therapeutics in Q2 2018 and held it in 12 quarters.
  • Trellus Management Company's Soleno Therapeutics position peaked at $1.31M in Q4 2019.
  • 47 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2021.

Based on Trellus Management Company's 13F filing for Q2 2021, filed 30 Jul 2021.